You are here: Home » Reuters » News
Business Standard

Merck Keytruda sales soar, but European application pulled


By Bill Berkrot(Reuters) - Merck & Co on Friday said quarterly sales of its Keytruda cancer immunotherapy exceeded $1 billion for the first time, but it withdrew an application for European use of the drug in lung cancer, raising questions about future sales.Merck's shares, which fell 6 percent to close at $58.24, were down another 3 percent at $56.68 after hours.Despite a near tripling in Keytruda sales to $1.05 billion, Merck said that the cost of a June cyber attack that temporarily crippled manufacturing coupled with lower sales of off-patent products caused its third-quarter revenue to ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Sat, October 28 2017. 03:31 IST